We are live on ! Find out more
BDRX icon

Biodexa Pharmaceuticals
BDRX

1 hedge funds and large institutions have $58.9K invested in Biodexa Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more capital inflows, than outflows

Capital inflows: $55.1K | Capital outflows: $35.8K

1.57% more ownership

Funds ownership: 3.54% → 5.11% (+1.6%)

Holders
1
Holders Change
+1
Holders Change %
–
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$55.1K

Top Sellers

Rank Fund Capital Flow
1
Cubist Systematic Strategies
Cubist Systematic Strategies
Connecticut
-$18.2K
2
Millennium Management
Millennium Management
New York
-$14K
3
Two Sigma Securities
Two Sigma Securities
New York
-$2.6K
4
Baader Bank Aktiengesellschaft
Baader Bank Aktiengesellschaft
Germany
-$865
5
Federation des caisses Desjardins du Quebec
Federation des caisses Desjardins du Quebec
Quebec, Canada
-$12

BDRX Hedge Fund Activity: Q3 2023 in Review

1 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q3 2023, worth a combined $58.9K — up 29% from $45.8K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new BDRX positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $55.1K. The largest seller was Cubist Systematic Strategies, cutting an estimated $18.2K.

  • 1 institutional investor held Biodexa Pharmaceuticals (BDRX) as of Q3 2023, up from 0 in Q2 2023.
  • Funds reported $58.9K of Biodexa Pharmaceuticals stock for Q3 2023, up 29% quarter-over-quarter.
  • 1 fund opened new Biodexa Pharmaceuticals positions in Q3 2023 and 0 closed out, a net change of +1 holder.
  • The largest Biodexa Pharmaceuticals buyer in Q3 2023 was Susquehanna International Group, an estimated $55.1K added.
  • The largest Biodexa Pharmaceuticals seller in Q3 2023 was Cubist Systematic Strategies, an estimated $18.2K sold.

Based on aggregated 13F filings for Q3 2023.